Literature DB >> 6328709

Clinical, haematological and parasitological response to treatment of visceral leishmaniasis in Kenya. A study of 64 patients.

P A Kager, P H Rees, F M Manguyu, K M Bhatt, B T Wellde, W T Hockmeyer, W H Lyerly.   

Abstract

Sixty four Kenyan patients with visceral leishmaniasis were treated with sodium stibogluconate (Pentostam) (40 patients) or various combinations of Pentostam and allopurinol (24 patients). Three patients, initially considered cured after Pentostam, relapsed but responded to further treatment. Sixty two were cured and two patients died. The treatment and the clinical, haematological and parasitological response to treatment are described in detail. If follow up is impossible or unlikely it is advised to continue treatment until parasitological cure is obtained. Prolonged courses of Pentostam, which were required in some patients, resulted in cures and apparently were non toxic. Consideration is to be given to extended treatment with Pentostam before more toxic drugs such as pentamidine and amphotericin B are given.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6328709

Source DB:  PubMed          Journal:  Trop Geogr Med        ISSN: 0041-3232


  3 in total

1.  Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised study.

Authors:  C P Thakur; M Kumar; P Kumar; B N Mishra; A K Pandey
Journal:  Br Med J (Clin Res Ed)       Date:  1988-06-04

2.  Experimental visceral leishmaniasis: role of trans-aconitic acid in combined chemotherapy.

Authors:  S Kar; K Kar; P K Bhattacharya; D K Ghosh
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

3.  Prognostic factors for mortality among patients with visceral leishmaniasis in East Africa: Systematic review and meta-analysis.

Authors:  Charles Abongomera; Saskia van Henten; Florian Vogt; Jozefien Buyze; Kristien Verdonck; Johan van Griensven
Journal:  PLoS Negl Trop Dis       Date:  2020-05-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.